<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00935259</url>
  </required_header>
  <id_info>
    <org_study_id>0000-140</org_study_id>
    <secondary_id>2009_609</secondary_id>
    <nct_id>NCT00935259</nct_id>
  </id_info>
  <brief_title>Lipid Biomarker Study in Men With Dyslipidemia After Simvastatin Treatment (Study MK-0000-140)(COMPLETED)</brief_title>
  <official_title>A Randomized, Placebo Controlled Clinical Trial to Evaluate the Effects of Simvastatin Treatment on Measurements of Lipidomic Biomarkers in Men With Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to provide human lipidomics standards with simvastatin
      treatment that were to be used for comparison with similar preclinical studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arachidonic Acid Level After 2 Weeks of Treatment</measure>
    <time_frame>2 weeks</time_frame>
    <description>Arachidonic acid level (20:4n6) in the cholesterol ester lipid class.
The mean reported was an adjusted mean, which was obtained from running a 2-period crossover model that had fixed treatment and period terms and a random participant term.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Lipidomic Levels After 2 Weeks of Treatment</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change in fasting blood cholesterol ester, lysophosphatidylcholine, phosphatidylcholine, phosphatidylethanolamine, and triacylglycerol levels compared to placebo.
The mean reported was an adjusted mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) Level</measure>
    <time_frame>2 weeks</time_frame>
    <description>Two days of standardized, pre-packaged meals were provided prior to the 10-hour fast required before blood collection. To assess how consumption of a meal would affect levels of plasma PCSK9, following each of the fasting blood draws, participants were asked to consume a high fat meal (heavy whipping cream + vanilla ice cream in a 1:4 ratio [dose = 162 g/m^2]) within 20 minutes. For the duration of the test, participants were to remain seated or recumbent until blood samples were drawn 4 h after meal completion.
The mean reported was an adjusted mean (defined in first outcome measure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Linoleic Acid Levels</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change in blood linoleic acid levels for Cholesterol Ester compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Delta 5 Desaturase Enzyme Activity Compared to Placebo</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change in fasting delta 5 desaturase enzyme activity compared to placebo. Delta 5 desaturase enzyme activity is defined as the ratios of C20:4n-6 to C20:3n-6 and C20:5n-3 to C20:4n-3.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Hypercholesterolemia, Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Simvastatin 40 mg first, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 40 mg tablets once daily for 2 weeks followed by placebo for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first, then simvastatin 40 mg once daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 2 weeks followed by simvastatin 40 mg once daily for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>40 mg once daily for 2 weeks</description>
    <arm_group_label>Simvastatin 40 mg first, then placebo</arm_group_label>
    <arm_group_label>Placebo first, then simvastatin 40 mg once daily</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks</description>
    <arm_group_label>Simvastatin 40 mg first, then placebo</arm_group_label>
    <arm_group_label>Placebo first, then simvastatin 40 mg once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is a Caucasian (including Hispanic) male

          -  Participant has a maximum waist size of 40 inches

          -  Participant does not currently use any lipid-altering medications

          -  Participant is in good health other than the diagnosis of dyslipidemia

        Exclusion Criteria:

          -  Participant has had stomach ulcers within the last 3 months

          -  Participant has had a heart attack in the last 6 months or has angina

          -  Participant has chronic heart failure

          -  Participant has a history of stroke, seizures, or major neurological disorder

          -  Participant has a history of cancer

          -  Participant has a gastrointestinal condition that affects bowel movements

          -  Participant has type 1 or 2 diabetes
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <results_first_submitted>December 17, 2010</results_first_submitted>
  <results_first_submitted_qc>January 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 20, 2012</results_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypercholesterolemia, Dyslipidemia, simvastatin, Zocor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Simvastatin 40 mg, Then Placebo</title>
          <description>Simvastatin 40 mg once daily for 2 weeks followed by placebo once daily for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Simvastatin 40 mg</title>
          <description>Placebo once daily for 2 weeks followed by simvastatin 40 mg daily for 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative (scheduling conflict)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All enrolled participants</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Arachidonic Acid Level After 2 Weeks of Treatment</title>
        <description>Arachidonic acid level (20:4n6) in the cholesterol ester lipid class.
The mean reported was an adjusted mean, which was obtained from running a 2-period crossover model that had fixed treatment and period terms and a random participant term.</description>
        <time_frame>2 weeks</time_frame>
        <population>Only participants with complete arachidonic acid data were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 40 mg</title>
            <description>Simvastatin 40 mg once daily for 2 weeks followed by placebo once daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily for 2 weeks followed by simvastatin 40 mg daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Arachidonic Acid Level After 2 Weeks of Treatment</title>
          <description>Arachidonic acid level (20:4n6) in the cholesterol ester lipid class.
The mean reported was an adjusted mean, which was obtained from running a 2-period crossover model that had fixed treatment and period terms and a random participant term.</description>
          <population>Only participants with complete arachidonic acid data were included.</population>
          <units>nmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259.1" spread="89.1"/>
                    <measurement group_id="O2" value="269.6" spread="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.455</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.4</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>52.1</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Blood Lipidomic Levels After 2 Weeks of Treatment</title>
        <description>Change in fasting blood cholesterol ester, lysophosphatidylcholine, phosphatidylcholine, phosphatidylethanolamine, and triacylglycerol levels compared to placebo.
The mean reported was an adjusted mean.</description>
        <time_frame>2 weeks</time_frame>
        <population>Only participants with complete blood lipidomic data were included.
For cholesterol ester 22:5n6, n=26 for the simvastatin arm and n=27 for the placebo arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 40 mg</title>
            <description>Simvastatin 40 mg once daily for 2 weeks followed by placebo for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily for 2 weeks followed by Simvastatin 40 mg once daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Blood Lipidomic Levels After 2 Weeks of Treatment</title>
          <description>Change in fasting blood cholesterol ester, lysophosphatidylcholine, phosphatidylcholine, phosphatidylethanolamine, and triacylglycerol levels compared to placebo.
The mean reported was an adjusted mean.</description>
          <population>Only participants with complete blood lipidomic data were included.
For cholesterol ester 22:5n6, n=26 for the simvastatin arm and n=27 for the placebo arm.</population>
          <units>nmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol ester lipid 16:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288.9" spread="102.1"/>
                    <measurement group_id="O2" value="345.1" spread="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol ester lipid 18:3n3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="4.8"/>
                    <measurement group_id="O2" value="14.4" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol ester lipid 20:3n6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="10.5"/>
                    <measurement group_id="O2" value="23.5" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol ester lipid 20:3n9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.1"/>
                    <measurement group_id="O2" value="1.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol ester lipid 22:5n6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.8"/>
                    <measurement group_id="O2" value="1.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol ester lipid 22:6n3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="5.1"/>
                    <measurement group_id="O2" value="14.8" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lysophosphatidyl-choline lipid 20:4n6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="3.8"/>
                    <measurement group_id="O2" value="10.3" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphatidyl-choline lipid 18:2n6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="684.8" spread="224.9"/>
                    <measurement group_id="O2" value="824.9" spread="196.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphatidyl-choline lipid 20:3n6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.4" spread="54.3"/>
                    <measurement group_id="O2" value="127.1" spread="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphatidyl-choline lipid 20:4n6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458.0" spread="138.4"/>
                    <measurement group_id="O2" value="443.2" spread="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphatidyl-choline lipid 22:5n3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="10.2"/>
                    <measurement group_id="O2" value="34.3" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphatidyl-choline lipid 22:5n6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="6.4"/>
                    <measurement group_id="O2" value="12.1" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphatidyl-ethanolamine lipid 18:2n6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="9.3"/>
                    <measurement group_id="O2" value="32.1" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triacylglycerol 16:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="788.3" spread="431.6"/>
                    <measurement group_id="O2" value="1005.1" spread="662.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triacylglycerol 20:3n9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="5.5"/>
                    <measurement group_id="O2" value="4.9" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cholesterol Ester 16:00</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-51.7</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cholesterol Ester 18:3n3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.5</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cholesterol Ester 20:3n6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.217</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cholesterol Ester 20:3n9</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.666</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cholesterol Ester 22:5n6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.776</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cholesterol Ester 22:6n3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lysophosphatidylcholine 20:4n6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.152</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phosphatidylcholine 18:2n6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-132.1</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phosphatidylcholine 20:3n6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.325</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.8</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phosphatidylcholine 20:4n6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.419</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>18.3</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phosphatidylcholine 22:5n3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.070</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.7</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phosphatidylcholine 22:5n6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.769</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phosphatidylethanolamine 18:2n6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.1</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Triacylglycerol 16:00</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-240.8</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Triacylglycerol 20:3n9</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.833</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) Level</title>
        <description>Two days of standardized, pre-packaged meals were provided prior to the 10-hour fast required before blood collection. To assess how consumption of a meal would affect levels of plasma PCSK9, following each of the fasting blood draws, participants were asked to consume a high fat meal (heavy whipping cream + vanilla ice cream in a 1:4 ratio [dose = 162 g/m^2]) within 20 minutes. For the duration of the test, participants were to remain seated or recumbent until blood samples were drawn 4 h after meal completion.
The mean reported was an adjusted mean (defined in first outcome measure).</description>
        <time_frame>2 weeks</time_frame>
        <population>Only participants with complete PCSK9 data were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 40 mg</title>
            <description>Simvastatin 40 mg once daily for 2 weeks followed by placebo for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily for 2 weeks followed by Simvastatin 40 mg once daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) Level</title>
          <description>Two days of standardized, pre-packaged meals were provided prior to the 10-hour fast required before blood collection. To assess how consumption of a meal would affect levels of plasma PCSK9, following each of the fasting blood draws, participants were asked to consume a high fat meal (heavy whipping cream + vanilla ice cream in a 1:4 ratio [dose = 162 g/m^2]) within 20 minutes. For the duration of the test, participants were to remain seated or recumbent until blood samples were drawn 4 h after meal completion.
The mean reported was an adjusted mean (defined in first outcome measure).</description>
          <population>Only participants with complete PCSK9 data were included.</population>
          <units>nmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.06" spread="2.34"/>
                    <measurement group_id="O2" value="4.69" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fasted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.47" spread="2.11"/>
                    <measurement group_id="O2" value="5.51" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fasted</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fed</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An unstructured covariance and Kenward Roger degrees of freedom were assumed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Linoleic Acid Levels</title>
        <description>Change in blood linoleic acid levels for Cholesterol Ester compared to placebo.</description>
        <time_frame>2 weeks</time_frame>
        <population>Only participants with complete blood linoleic acid data were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 40 mg</title>
            <description>Simvastatin 40 mg once daily for 2 weeks followed by placebo for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily for 2 weeks followed by Simvastatin 40 mg once daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Linoleic Acid Levels</title>
          <description>Change in blood linoleic acid levels for Cholesterol Ester compared to placebo.</description>
          <population>Only participants with complete blood linoleic acid data were included.</population>
          <units>nmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1184.7" spread="393.4"/>
                    <measurement group_id="O2" value="1504.7" spread="327.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Delta 5 Desaturase Enzyme Activity Compared to Placebo</title>
        <description>Change in fasting delta 5 desaturase enzyme activity compared to placebo. Delta 5 desaturase enzyme activity is defined as the ratios of C20:4n-6 to C20:3n-6 and C20:5n-3 to C20:4n-3.</description>
        <time_frame>2 weeks</time_frame>
        <population>Only participants with complete fasting delta 5 desaturase enzyme activity data were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 40 mg</title>
            <description>Simvastatin 40 mg once daily for 2 weeks followed by placebo for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily for 2 weeks followed by Simvastatin 40 mg once daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Delta 5 Desaturase Enzyme Activity Compared to Placebo</title>
          <description>Change in fasting delta 5 desaturase enzyme activity compared to placebo. Delta 5 desaturase enzyme activity is defined as the ratios of C20:4n-6 to C20:3n-6 and C20:5n-3 to C20:4n-3.</description>
          <population>Only participants with complete fasting delta 5 desaturase enzyme activity data were included.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol ester c20:4n6 / c20:3n6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2234" spread="3.413"/>
                    <measurement group_id="O2" value="11.5662" spread="3.684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol Ester c20:5n3/c20:4n3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9161" spread="7.738"/>
                    <measurement group_id="O2" value="16.3024" spread="9.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cholesterol ester c20:4n6 / c20:3n6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.247</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cholesterol ester c20:5n3 / c20:4n3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.151</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Simvastatin</title>
          <description>Simvastatin 40 mg tablets once daily for 2 weeks in either Period 1 or Period 2</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo to simvastatin tablets once daily for 2 weeks in either Period 1 or Period 2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publications should include input from the investigator(s), and Sponsor personnel. Such input should be reflected in publication authorship. The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

